Inside the research
Kenvue Inc.
KVUE Research profile · latest available data
Price overview
$17.80
▲ +0.19 (+1.1%)
| 52w hi | $19.38 |
|---|---|
| 52w lo | $13.30 |
| Vol | 12.56M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.08
| Short | -0.07 |
|---|---|
| Medium | -0.12 |
| Long | -0.01 |
computed 2026-09-27
Key fundamentals
Kenvue Inc.
Consumer Defensive · Household & Personal Products
| Market cap | $34.19B |
|---|---|
| Enterprise value | $41.69B |
| Trailing P/E | 20.94x |
| Forward P/E | 14.36x |
| EV / EBITDA | 11.98x |
| P / S (ttm) | 2.22x |
| Profit margin | 10.8% |
| Return on equity | 15.6% |
| Revenue growth | +3.0% |
| Earnings growth | +8.5% |
| Debt / equity | 81.62 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.25 | |
| Sector | -0.01 | |
| Technical | -0.09 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Risk Metrics
| Beta vs SPX | 0.18 |
|---|---|
| Corr SPX | 0.10 |
| Annual vol | 28.7% |
| Annual ret | -8.7% |
| Sharpe | -0.30 |
| Max DD | -42.3% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $19.50 |
|---|---|
| High / Low | $23.00 / $18.00 |
| Median | $19.00 |
| Analysts | 12 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 1 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-15 | Citigroup | → Neutral |
| 2026-04-14 | Barclays | → Equal-Weight |
| 2026-04-07 | UBS | → Neutral |
| 2026-03-06 | Barclays | → Equal-Weight |
| 2026-02-18 | UBS | → Neutral |
| 2026-02-18 | Citigroup | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-05-22 | Shareholder Vote | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-04-15 | Officer / Director Change, Exhibits | read |
| 2026-02-17 | Earnings Release, Restructuring… | read |
| 2026-02-12 | Officer / Director Change | read |
| 2026-01-29 | Shareholder Vote, Reg FD Disclosure… | read |
| 2026-01-16 | Other Material Event | read |
| 2025-11-03 | Material Agreement, Officer / Director Change… | read |
| 2025-11-03 | Earnings Release, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-07-14 | Earnings Release, Officer / Director Change… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Dasgupta Anindya | Group President APAC | Option exercise | 16.42K | — |
| 2026-06-10 | Howlett Heather | CFO & CAO | Sell | 3.70K | $66.99K |
Flow & Concentration
| Insider 180d net | -$66.99K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 96.9% |
| HHI | 3,293 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $3.00B | 157.05M |
| State Street Corp | $2.32B | 121.62M |
| Millennium Management | $713.86M | 37.36M |
| Capital Research / Capital World | $260.64M | 13.64M |
| Citadel Advisors | $256.60M | 13.43M |
| Renaissance Technologies | $172.46M | 9.02M |
| AQR Capital Management | $32.08M | 1.69M |
| Bridgewater Associates | $5.95M | 311.24K |
| T. Rowe Price Group | $283.42K | 14.83M |
As of 2026-06-30
Dividends
| Yield (TTM) | 2.34% |
|---|---|
| $ / share (TTM) | $0.42 |
| 5y CAGR | — |
Annual dividend per share
| 2023 | $0.40 |
|---|---|
| 2024 | $0.81 |
| 2025 | $0.83 |
| 2026 | $0.21 |
SEC Filings
The Long Run
FY 2023–2025 · 3 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $15.12B | -1.0% | |
| Gross profit | $8.79B | +112.0% | |
| Operating income | $2.51B | -3.1% | |
| Net income | $1.66B | +94.9% | |
| Cash from ops | $2.20B | -16.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $17.59 | $17.84 | $17.56 | $17.80 | 12.56M |
| Sep 24 | $17.77 | $17.88 | $17.61 | $17.61 | 17.49M |
| Sep 23 | $17.84 | $17.90 | $17.64 | $17.67 | 16.17M |
| Sep 22 | $17.95 | $17.99 | $17.84 | $17.86 | 14.29M |
| Sep 21 | $17.63 | $17.73 | $17.49 | $17.67 | 25.68M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →